RNA Binding Protein IGF2BP3 Rehabilitates Glycolysis of Vascular Endothelial Cells to Protect the ox-LDL-induced Cellular Injury via Stabilizing LDHA mRNA
- PMID: 40159306
- DOI: 10.1007/s12013-025-01735-0
RNA Binding Protein IGF2BP3 Rehabilitates Glycolysis of Vascular Endothelial Cells to Protect the ox-LDL-induced Cellular Injury via Stabilizing LDHA mRNA
Abstract
Vascular endothelial cells (VECs) dysfunction has been revealed to be a major cause of various cardiovascular diseases. Yet, the precise cellular and molecular mechanisms of VECs injury remain elusive. This study aims to investigate the roles and molecular mechanisms of RNA binding protein IGF2BP3 in vascular endothelial cell injury caused by oxidized low-density lipoprotein (ox-LDL). HUVECs were treated with ox-LDL to induce endothelial cell injury, and the cellular responses to ox-LDL were assessed using cell viability and apoptosis assays. IGF2BP3 was expressed at low levels in vascular tissues from atherosclerosis patients. Treatment with ox-LDL significantly decreased the expression of IGF2BP3 in HUVECs. Overexpression of IGF2BP3 effectively reduced the injury induced by ox-LDL. Glucose metabolism enzymes were significantly downregulated in vascular tissues from atherosclerosis patients and in HUVECs treated with ox-LDL, leading to suppressed glucose metabolism. IGF2BP3 upregulated the glucose metabolism enzyme LDHA to alleviate the injury caused by ox-LDL in HUVECs. Analysis of the LDHA sequence revealed the presence of an IGF2BP3 binding motif in its 3'UTR. Further experiments including RNA pull-down, RNA IP, and RNA stability assays confirmed the specific binding of IGF2BP3 to the 3'UTR region of LDHA, stabilizing its transcripts. Rescue experiments demonstrated that IGF2BP3 mitigated vascular endothelial cell injury by regulating LDHA-mediated glucose metabolism. The outcomes of this study elucidate the protective roles of IGF2BP3 in safeguarding vascular endothelial cells against injury.
Keywords: Glucose metabolism; HUVEC; IGF2BP3; LDHA; RNA binding protein; Vascular endothelial cell; ox-LDL.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Compliance with Ethical Standards. Conflict of Interest: The authors declare no competing interests. Ethical Approval: This study was approved by the Ethics Committee of The First People’s Hospital of Linping District, Hangzhou City, China (#2021-088). Consent to Participate: Informed consent was obtained from all participants. Consent to Publish: All authors have read and agreed to publish this study.
Similar articles
-
IGF2BP3 stabilizes SESN1 mRNA to mitigate oxidized low-density lipoprotein-induced oxidative stress and endothelial dysfunction in human umbilical vein endothelial cells by activating Nrf2 signaling.Prostaglandins Other Lipid Mediat. 2024 Jun;172:106832. doi: 10.1016/j.prostaglandins.2024.106832. Epub 2024 Mar 7. Prostaglandins Other Lipid Mediat. 2024. PMID: 38460759
-
LncRNA MIR4697HG Alleviates Endothelial Cell Injury and Atherosclerosis Progression in Mice via the FUS/ANXA5 Axis.Biochem Genet. 2024 Aug;62(4):3155-3173. doi: 10.1007/s10528-023-10542-2. Epub 2023 Dec 11. Biochem Genet. 2024. PMID: 38082058
-
Extracellular vesicle-mediated transfer of lncRNA CLDN10-AS1 aggravates low-density lipoprotein-induced vascular endothelial injury.Physiol Genomics. 2022 Dec 1;54(12):471-485. doi: 10.1152/physiolgenomics.00094.2022. Epub 2022 Oct 17. Physiol Genomics. 2022. PMID: 36250558
-
TRIM59 attenuates ox-LDL-induced endothelial cell inflammation, apoptosis, and monocyte adhesion through AnxA2.Ann Transl Med. 2023 Jan 31;11(2):42. doi: 10.21037/atm-22-6044. Epub 2023 Jan 11. Ann Transl Med. 2023. PMID: 36819529 Free PMC article.
-
UHRF1 inhibition mitigates vascular endothelial cell injury and ameliorates atherosclerosis in mice via regulating the SMAD7/YAP1 axis.Mol Immunol. 2024 Jun;170:119-130. doi: 10.1016/j.molimm.2024.04.001. Epub 2024 Apr 23. Mol Immunol. 2024. PMID: 38657333
References
-
- Onnis, C., Virmani, R., Kawai, K., Nardi, V., Lerman, A., & Cademartiri, F., et al. (2024). Coronary artery calcification: current concepts and clinical implications. Circulation, 149(3), 251–266. https://doi.org/10.1161/CIRCULATIONAHA.123.065657 . - DOI - PubMed - PMC
-
- Walsh, R., Jurgens, S. J., Erdmann, J., & Bezzina, C. R. (2023). Genome-wide association studies of cardiovascular disease. Physiological Reviews, 103(3), 2039–2055. https://doi.org/10.1152/physrev.00024.2022 . - DOI - PubMed
-
- Trimm, E., & Red-Horse, K. (2023). Vascular endothelial cell development and diversity. Nature Reviews Cardiology, 20(3), 197–210. https://doi.org/10.1038/s41569-022-00770-1 . - DOI - PubMed
-
- Dudley, A. C., & Griffioen, A. W. (2023). Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis, 26(3), 313–347. https://doi.org/10.1007/s10456-023-09876-7 . - DOI - PubMed - PMC
-
- Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., & Kuca, K., et al. (2023). Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Archives of Toxicology, 97(10), 2499–2574. https://doi.org/10.1007/s00204-023-03562-9 . - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources
Miscellaneous